Completed PHASE2 INTERVENTIONAL 3-arm NCT00659802

Phase II Study of HMPL-004 in Patients With Ulcerative Colitis

A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis With or Without Mesalamine

Sponsor: Hutchison Medipharma Limited

Conditions Ulcerative Colitis

Interventions HMPL-004 high dose HMPL-004 low dose Placebo

Updated 10 times since 2017 Last updated: Jul 6, 2020 Started: Feb 7, 2008 Primary completion: Oct 13, 2009 Completion: Oct 13, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ulcerative Colitis and is currently completed. Hutchison Medipharma Limited leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Oct 2022 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Jan 2021 — Oct 2022 [monthly]

Completed PHASE2
Aug 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Aug 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hutchison Medipharma Limited

Data source: Hutchmed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.